Literature DB >> 33222469

Chinese herbal medicine Buyang Huanwu Decoction combined with acupuncture to treat sequela of apoplexy: a meta-analysis of randomized controlled trials.

Meng-Jie Zeng1, Lin-Jun Li2, Zhi-Quan Wu3.   

Abstract

BACKGROUND: Buyang Huanwu Decoction combined with acupuncture has a wide range of applications in the treatment of stroke sequelae, and there are many clinical trial reports. We systematically evaluated the clinical efficacy and safety of Buyang Huanwu Decoction combined with acupuncture in treating stroke sequelae, and evaluated overall research quality.
METHODS: We searched 7 databases which includes the Chinese Journal Full-text Database (CNKI), VIP Database (VIP), China Biomedicine (SinoMed), Wanfang Database and PubMed, Cochrane Central, EMBASE from January 2010 to December 2019 Literature references. We selected randomized controlled trials that tested the effects of Buyang Huanwu Decoction combined with acupuncture on stroke sequelae. The authors extracted data and independently assessed quality. We used RevMan 5.3.0 software to analyze the data of randomized trials.
RESULTS: A total of 7 articles were identified, including 902 patients. The overall quality of the included trials was poor, and one of them was moderate. Meta-analysis results showed that the experimental group of Buyang Huanwu decoction combined with acupuncture treatment of stroke sequela compared with the control group clearly improved the clinical efficacy improved the clinical efficacy rate (RR 1.18, 95% CI: 1.12, 1.25), P<0.00001]. Among them, three trials included the incidence of adverse reactions (RR 0.22, 95% CI: 0.09, 0.52, P=0.0006), which also confirmed the safety of its treatment.
CONCLUSIONS: Buyang Huanwu Decoction combined with acupuncture is an effective therapy to ameliorate the clinical symptoms of stroke sequelae. In order to further determine the effectiveness and safety of Buyang Huanwu Decoction combined with acupuncture in treating stroke sequelae, more rigorous design, multicenter and prospective RCT must be carried out.

Entities:  

Keywords:  Buyang Huanwu Decoction; Chinese herbal medicine; acupuncture; metaanalysis of randomized controlled trials; sequela of apoplexy

Mesh:

Substances:

Year:  2020        PMID: 33222469     DOI: 10.21037/apm-20-1092

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  5 in total

1.  Efficacy and safety of Buyang Huanwu-Tang (Boyang Hwano-Tang) in patients with vascular dementia: A protocol of systematic review and meta analysis.

Authors:  Hye Jeong Kook; Da Woon Kim; Ju Yeon Kim; Sang Ho Kim; In Chul Jung
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

2.  Efficacy and safety of Buyang Huanwu decoction in the treatment of varicose veins of the lower extremities: A protocol of randomized controlled trial.

Authors:  Chuanyong Li; Weijian Fan; Zhichang Pan; Guangfeng Zheng; Qiang Zhang; Jianjie Rong
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

3.  Study on Active Components of Cuscuta chinensis Promoting Neural Stem Cells Proliferation: Bioassay-Guided Fractionation.

Authors:  Hanze Wang; Xiaomeng Hou; Bingqi Li; Yang Yang; Qiang Li; Yinchu Si
Journal:  Molecules       Date:  2021-11-02       Impact factor: 4.411

4.  Study on the Effect of Self-Made Lifei Dingchuan Decoction Combined with Western Medicine on Cough Variant Asthma.

Authors:  Jiachun Li; Ziliang Huang; Keying Li; Xiaoyun Jian; Binghui Liang
Journal:  Comput Math Methods Med       Date:  2022-09-12       Impact factor: 2.809

5.  Experimental Evidence of Buyang Huanwu Decoction and Related Modern Preparations (Naoxintong Capsule and Yangyin Tongnao Granule) in Treating Cerebral Ischemia: Intestinal Microorganisms and Transcriptomics in Rats.

Authors:  Junjun Yin; Jiehong Yang; Buchang Zhao; Chao Zhao; Wei Fu; Yu He; Miaolin Zeng; Yuting Yang; Xiaoyu Wei; Zhishan Ding; Jingxian Bai; Haitong Wan; Huifen Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-21       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.